CA3104432A1 - Combinatorial gene therapy - Google Patents

Combinatorial gene therapy Download PDF

Info

Publication number
CA3104432A1
CA3104432A1 CA3104432A CA3104432A CA3104432A1 CA 3104432 A1 CA3104432 A1 CA 3104432A1 CA 3104432 A CA3104432 A CA 3104432A CA 3104432 A CA3104432 A CA 3104432A CA 3104432 A1 CA3104432 A1 CA 3104432A1
Authority
CA
Canada
Prior art keywords
transgene
vector
combination therapy
type
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3104432A
Other languages
English (en)
French (fr)
Inventor
Samir El Andaloussi
Per Lundin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evox Therapeutics Ltd
Original Assignee
Evox Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evox Therapeutics Ltd filed Critical Evox Therapeutics Ltd
Publication of CA3104432A1 publication Critical patent/CA3104432A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Manufacturing & Machinery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3104432A 2018-06-22 2019-06-21 Combinatorial gene therapy Pending CA3104432A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1810301.0A GB201810301D0 (en) 2018-06-22 2018-06-22 Combinatorial gene therapy
GB1810301.0 2018-06-22
PCT/EP2019/066471 WO2019243574A1 (en) 2018-06-22 2019-06-21 Combinatorial gene therapy

Publications (1)

Publication Number Publication Date
CA3104432A1 true CA3104432A1 (en) 2019-12-26

Family

ID=63042788

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3104432A Pending CA3104432A1 (en) 2018-06-22 2019-06-21 Combinatorial gene therapy

Country Status (14)

Country Link
US (1) US20210252164A1 (https=)
EP (1) EP3810206B1 (https=)
JP (1) JP2021528407A (https=)
KR (1) KR20210024040A (https=)
CN (1) CN112955185A (https=)
AU (1) AU2019289998A1 (https=)
BR (1) BR112020026260A2 (https=)
CA (1) CA3104432A1 (https=)
GB (1) GB201810301D0 (https=)
IL (1) IL279584A (https=)
MX (1) MX2020013865A (https=)
SG (1) SG11202012727SA (https=)
WO (1) WO2019243574A1 (https=)
ZA (1) ZA202100244B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022315530A1 (en) 2021-07-20 2024-01-18 Ags Therapeutics Sas Extracellular vesicles from microalgae, their preparation, and uses
WO2023144127A1 (en) 2022-01-31 2023-08-03 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon administration, and uses
WO2023232976A1 (en) 2022-06-03 2023-12-07 Ags Therapeutics Sas Extracellular vesicles from genetically-modified microalgae containing endogenously-loaded cargo, their preparation, and uses
WO2024088808A1 (en) 2022-10-24 2024-05-02 Ags Therapeutics Sas Extracellular vesicles from microalgae, their biodistribution upon intranasal administration, and uses thereof
WO2025176843A1 (en) 2024-02-21 2025-08-28 Ags Therapeutics Sas Microalgae extracellular vesicle based gene therapy vectors (mev-gtvs), their preparation, and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001273150A1 (en) * 2000-07-20 2002-02-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2500434A1 (en) * 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
CN102813942A (zh) * 2012-08-15 2012-12-12 钟志容 脂质超声微泡介导的腺相关病毒基因转染制剂及制备工艺
WO2015002956A1 (en) * 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
EP3842537A1 (en) * 2013-12-30 2021-06-30 CureVac AG Artificial nucleic acid molecules
CA2960164A1 (en) * 2014-09-05 2016-03-10 Exerkine Corporation Methods of producing and using exersomes and bioengineered exersomes
WO2016044947A1 (en) * 2014-09-26 2016-03-31 Exerkine Corporation Exosomes useful to treat lysosomal storage disease
AU2017241534A1 (en) * 2016-03-28 2018-10-04 The Regents Of The University Of California Method and composition for treating neuronal hyper-excitability
GB2568255A (en) * 2017-11-08 2019-05-15 Evox Therapeutics Ltd Exosomes comprising RNA therapeutics

Also Published As

Publication number Publication date
JP2021528407A (ja) 2021-10-21
BR112020026260A2 (pt) 2021-03-23
IL279584A (en) 2021-03-01
KR20210024040A (ko) 2021-03-04
EP3810206A1 (en) 2021-04-28
ZA202100244B (en) 2022-07-27
GB201810301D0 (en) 2018-08-08
US20210252164A1 (en) 2021-08-19
EP3810206B1 (en) 2024-01-24
SG11202012727SA (en) 2021-01-28
WO2019243574A1 (en) 2019-12-26
AU2019289998A1 (en) 2021-02-04
CN112955185A (zh) 2021-06-11
MX2020013865A (es) 2021-03-25

Similar Documents

Publication Publication Date Title
EP3810206B1 (en) Combinatorial gene therapy
US20230201370A1 (en) Exosomes comprising therapeutic polypeptides
JP7208231B2 (ja) 肺組織への標的化薬物及び遺伝子送達のためのシンシチンの使用
KR20200081487A (ko) 단백질 조작된 세포외 소포
GB2568255A (en) Exosomes comprising RNA therapeutics
US20200261589A1 (en) Use of a Syncytin for Targeting Drug and Gene Delivery to Regenerate Muscle Tissue
EP4329720A1 (en) Modified extracellular vesicles (evs) with improved half-life
KR20230034334A (ko) 개선된 반감기를 갖는 세포외 소포
Kushwah et al. Potential of helper-dependent adenoviral vectors in modulating airway innate immunity
HK40042395A (en) Exosomes comprising therapeutic polypeptides
Evans et al. Selected Oral Presentations
Lettner et al. Trans-splicing gene therapy in the KRT14 gene
HK40006325B (en) Exosomes comprising therapeutic polypeptides

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220920